Cochrane Abstracts
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients New search for studies and content updated (conclusions changed)
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients New search for studies and content updated (conclusions changed) is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients New Search for Studies and Content Updated (conclusions Changed)." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434416/all/Target_of_rapamycin_inhibitors__TOR‐I. Accessed 15 January 2021.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients New search for studies and content updated (conclusions changed). Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434416/all/Target_of_rapamycin_inhibitors__TOR‐I. Accessed January 15, 2021.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients New search for studies and content updated (conclusions changed). In Cochrane Abstracts Retrieved January 15, 2021, from https://evidence.unboundmedicine.com/evidence/view/Cochrane/434416/all/Target_of_rapamycin_inhibitors__TOR‐I
Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients New Search for Studies and Content Updated (conclusions Changed) [Internet]. In: Cochrane Abstracts. [cited 2021 January 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434416/all/Target_of_rapamycin_inhibitors__TOR‐I.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients New search for studies and content updated (conclusions changed)
ID - 434416
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434416/all/Target_of_rapamycin_inhibitors__TOR‐I
DB - Evidence Central
DP - Unbound Medicine
ER -
